A federal jury in California found that Kite Pharma - now part of Gilead Sciences - violated a patent from Memorial Sloan Kettering Cancer Center and licensed to BMS' Juno Therapeutics in developing the CAR-T therapy Yescarta, approved in 2017.
Non-binding vote by MEDCAC supports use of PROs in CAR-T clinical trials, drawing opposition from industry and oncology groups.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
CMS could run trials of CAR-Ts in lymphoma if unsure of their similarity on benefit to patients and ancillary service costs, Dr. Peter Bach writes.
The clinical trial of the CAR-T - a potential competitor to bluebird bio's - will start enrolling patients later this year.
Analysts had forecast a blockbuster year for life science M&As, with the tax reforms taking effect and Big Pharma scrambling for late-stage assets. Less than one month in, the predictions seem to be coming true.
An NIH study has shown that giving HIV drugs when patients are initially diagnosed with the disease is more effective than waiting for the white blood cell counts to drop.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Tech venture behemoth Arch Venture Partners has announced its eighth venture fund just closed with more than $400 million in subscriptions and, as co-founder and managing director Robert Nelson just told Forbes, it’s looking to fund companies with “contrarian philosophies.” Alex Konrad over at Forbes writes: That money will go to funding companies that cofounder and […]
The burgeoning cancer immunotherapy space has tons of investors, to be sure, but perhaps no other startup has ever been as well-capitalized as Seattle-based Juno Therapeutics. The company now has raised $310 million in the past year, having just closed a $134 million Series B round that comes right on the heels of its $176 million […]
Underscoring the hot investment prospects of cancer immunotherapy, Juno Therapeutics has secured additional funding from investors to close its Series A at $176 million, according to a company statement. The company is developing two immunotherapy platforms to treat hematologic and solid tumor cancers and reduce the toxicity associated with chemotherapeutics. The completion of the A […]
Amazon founder Jeff Bezos has taken an interest in cancer immunotherapies. The investment in life science innovation marks a shift in his personal investment focus from the technology startups that he has favored. His investment in Juno Therapeutics through his personal investment company Bezos Expeditions helps expand its Series A round from $120 million in […]
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.